NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $12.81 -0.29 (-2.21 %) (As of 01/23/2019 04:00 PM ET)Previous Close$13.10Today's Range$12.51 - $13.3252-Week Range$4.77 - $22.39Volume1.48 million shsAverage Volume1.71 million shsMarket Capitalization$1.18 billionP/E Ratio-19.71Dividend YieldN/ABeta1.96 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Receive ARWR News and Ratings via Email Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARWR Previous Symbol CUSIPN/A Webwww.arrowheadpharma.com Phone626-304-3400Debt Debt-to-Equity Ratio0.02 Current Ratio6.37 Quick Ratio6.37Price-To-Earnings Trailing P/E Ratio-19.71 Forward P/E Ratio8.60 P/E GrowthN/A Sales & Book Value Annual Sales$16.14 million Price / Sales73.20 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book11.86Profitability EPS (Most Recent Fiscal Year)($0.65) Net Income$-54,450,000.00 Net Margins-337.32% Return on Equity-57.18% Return on Assets-49.53%Miscellaneous Employees95 Outstanding Shares92,225,000Market Cap$1.18 billion OptionableOptionable Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions What is Arrowhead Pharmaceuticals' stock symbol? Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR." How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its earnings results on Tuesday, December, 11th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.05. The biotechnology company had revenue of $11.26 million for the quarter, compared to analysts' expectations of $3.73 million. Arrowhead Pharmaceuticals had a negative net margin of 337.32% and a negative return on equity of 57.18%. View Arrowhead Pharmaceuticals' Earnings History. When is Arrowhead Pharmaceuticals' next earnings date? Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, February 8th 2019. View Earnings Estimates for Arrowhead Pharmaceuticals. What price target have analysts set for ARWR? 6 equities research analysts have issued 1-year price objectives for Arrowhead Pharmaceuticals' shares. Their predictions range from $11.68 to $25.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $21.3633 in the next year. This suggests a possible upside of 66.8% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals. What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals. What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock? Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock: 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $24 PT on Arrowhead Pharmaceuticals, following release of late-breaker abstracts for the Liver Meeting (AASLD) being held on San Francisco. Additional data from Arrowhead’s lead programs in hepatitis B virus (HBV) and alpha-1 antitrypsin (AAT) were made available further supporting activity of both compounds in chronic HBV patients and healthy volunteers, respectively. We believe these initial data add readthrough going into the meeting and further underscore Arrowhead’s ability to establish a platform RNAi company." (10/11/2018) 2. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018) Has Arrowhead Pharmaceuticals been receiving favorable news coverage? News stories about ARWR stock have been trending negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near future. Who are some of Arrowhead Pharmaceuticals' key competitors? Some companies that are related to Arrowhead Pharmaceuticals include Alkermes (ALKS), Catalent (CTLT), United Therapeutics (UTHR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Array Biopharma (ARRY), Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), Emergent Biosolutions (EBS) and Ascendis Pharma A/S (ASND). Who are Arrowhead Pharmaceuticals' key executives? Arrowhead Pharmaceuticals' management team includes the folowing people: Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)Dr. Bruce D. Given, Chief Operating Officer (Age 65)Mr. Patrick O'Brien, Gen. Counsel (Age 55)Mr. Peter B. Leone MBA, VP of Strategic Bus. Initiatives (Age 62) Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Capital Wealth Advisors (0.03%), IFP Advisors Inc (0.02%) and Wealth Architects LLC (0.01%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals. Which institutional investors are selling Arrowhead Pharmaceuticals stock? ARWR stock was sold by a variety of institutional investors in the last quarter, including Vanguard Capital Wealth Advisors. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Insider Buying and Selling for Arrowhead Pharmaceuticals. Which institutional investors are buying Arrowhead Pharmaceuticals stock? ARWR stock was acquired by a variety of institutional investors in the last quarter, including IFP Advisors Inc and Wealth Architects LLC. View Insider Buying and Selling for Arrowhead Pharmaceuticals. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Arrowhead Pharmaceuticals' stock price today? One share of ARWR stock can currently be purchased for approximately $12.81. How big of a company is Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals has a market capitalization of $1.18 billion and generates $16.14 million in revenue each year. The biotechnology company earns $-54,450,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Arrowhead Pharmaceuticals employs 95 workers across the globe. What is Arrowhead Pharmaceuticals' official website? The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com. How can I contact Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected] MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 314 (Vote Outperform)Underperform Votes: 221 (Vote Underperform)Total Votes: 535MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2019 by MarketBeat.com StaffFeatured Article: What is dollar cost averaging (DCA)?